Study of BMS-275183 in Patients With Pre-treated Non-small Cell Lung Cancer
A Randomized, Two-Cohort Phase II Study of Two Doses of BMS-275183 Given on a Weekly Schedule in Patients With Pre-Treated Non-Small Cell Lung Cancer
Sponsor: Bristol-Myers Squibb
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Bristol-Myers Squibb
- Highly Sensitised Dialysis Patients · Phase PHASE2 · Oct 2025
- Colorectal Neoplasms · Phase PHASE3 · Jul 2025
- Colitis, Ulcerative · May 2025
- Genital Psoriasis · Apr 2025
- Hepatic Insufficiency · Phase PHASE1 · Apr 2025
More terminations from Bristol-Myers Squibb
Other Non-small Cell Lung Cancer trials with similar outcome
This PHASE2 trial investigates Non-small Cell Lung Cancer and is currently terminated or withdrawn. Bristol-Myers Squibb leads this study, which shows 7 recorded versions since 2026 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Apr 2022 [monthly]
Terminated PHASE2
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amsterdam, Netherlands , Atlanta, United States , Barcelona, Spain , Belfort, France , Besançon, France , Brussels, Belgium , Detroit, United States , Groningen, Netherlands , Leuven, Belgium , Madrid, Spain and 10 more locations